Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Impact of dementia on in-hospital outcomes in hematopoietic stem cell transplant (HSCT) recipients: A nationwide cohort study

Laith Sorour, Ben Varghese, Tasneem Anagreh et al. Nov 03, 2025 pp. 5968-5968 10.1182/blood-2025-5968

Abstract Background Hematopoietic stem cell transplant (HSCT) is a curative treatment for many hematologic diseases but requires rigorous me...

Beyond approval: Lymphoma drugs and real-world representation (2015–2025)

Sam Ranger, Maya Birhiray, Ruemu Birhiray Nov 03, 2025 pp. 4421-4421 10.1182/blood-2025-4421

Abstract INTRODUCTION Clinical trial generalizability remains an unmet goal in oncology clinical research. Generalizability refers to the abi...

Survival outcomes following second hematopoietic cell transplantation in lymphoma and leukemia: A single-center analysis

Yousef Alghzawi, Bara Hammadeh, Nesreen Alhamwi et al. Nov 03, 2025 pp. 7802-7802 10.1182/blood-2025-7802

Abstract Background: Allogeneic hematopoietic cell transplantation (allo-HCT) offers curative potential for aggressive hematologic malignanc...

Treatment of pediatric patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy: Preliminary findings from the Phase Ib/II CATULUS trial

Sara Ghorashian, Michael Pulsipher, Juliana Silva et al. Nov 03, 2025 pp. 3337-3337 10.1182/blood-2025-3337

Abstract Background: Obe-cel is an autologous, fast off-rate 4-1BB-ζ CD19-directed CAR T-cell therapy that demonstrated long-term efficacy an...

Azin1/tecr reprograms fatty acid metabolism to drive Acute Myeloid Leukemia progression

Meng Yang, Fengjiao Wang, Yifei Wang et al. Nov 03, 2025 pp. 1464-1464 10.1182/blood-2025-1464

Abstract Acute myeloid leukemia (AML) is a clonal hematopoietic stem/progenitor cell disorder driven by aberrant proliferation, and undergoe...

FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML

LaQuita Jones, Akhtar Khadaroo, Riya Tiwari et al. Nov 03, 2025 pp. 5049-5049 10.1182/blood-2025-5049

Abstract FMS-like tyrosine kinase 3 (FLT3) mutations occur in ~20–30% of acute myeloid leukemia (AML) cases and have been effectively target...

Emicizumab prophylaxis in pups and mtps with severe haemophilia: The pednet real world experience in 80 infants

Marloes de Kovel, Gili Kenet, Jayashree Motwani et al. Nov 03, 2025 pp. 305-305 10.1182/blood-2025-305

Abstract Emicizumab (Hemlibra®, Roche) is a humanized bispecific antibody used for subcutaneous prophylaxis in children of any age and adult...

Improving karyotype success for myelomatch: Evidence-based culturing optimization for rapid AML screening - an NCI myelomatch and SWOG report

Xiaoyu Qu, Shane McClung, Nicole Shepherd et al. Nov 03, 2025 pp. 3473-3473 10.1182/blood-2025-3473

Abstract Introduction As a key screening test for the NCI myeloMATCH clinical trial, karyotyping detects aberrations at single-cell resolutio...

Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)

Esther Natalie Oliva, Marta Riva, Chiara Frairia et al. Nov 03, 2025 pp. 5631-5631 10.1182/blood-2025-5631

Abstract Background: Myelodysplastic neoplasms (MDS) with deletion 5q (del5q) are characterized by <5% bone marrow blasts and either...

An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma

Ricky Nelles, Mark Meerson, Soi Law et al. Nov 03, 2025 pp. 5338-5338 10.1182/blood-2025-5338

Abstract Introduction: Bendamustine-based immunochemotherapy (ICT) is a standard frontline regimen for follicular lymphoma (FL) but has limi...

Application of hi-c sequencing to detect cryptic and novel structural aberrations in lymphoid neoplasms

Krasimira Rozenova, Tarsheen Sethi, Deepika Kumar et al. Nov 03, 2025 pp. 4355-4355 10.1182/blood-2025-4355

Abstract Background: The diagnosis of lymphoid malignancies primarily relies on histopathologic evaluation, immunophenotypic profiling, and...

Mortality trends in patients with co-occurring hematologic malignancies and heart failure in the United States population: A 25-year analysis using the CDC wonder database

Abdullah Bin Usman, Amna Amjad, Vedant Shah et al. Nov 03, 2025 pp. 6191-6191 10.1182/blood-2025-6191

Abstract Background: Hematologic malignancies (HM), also known as blood cancers, primarily include leukemia, lymphoma, and multiple myeloma....

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

Elena Maroto Martin, Marina He, Radia Khan et al. Nov 03, 2025 pp. 2332-2332 10.1182/blood-2025-2332

Abstract BCMA-directed CAR T cell therapies have improved outcomes for multiple myeloma (MM), and several other targeted CAR T cell therapie...

Osimertinib synergizes selinexor on anti-tumor effect by targeting c-MYC in T-cell acute lymphoblastic leukemia

Rushuang Xu, Dongfeng Zeng, Xi Li Nov 03, 2025 pp. 6888-6888 10.1182/blood-2025-6888

Abstract Background Adult T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignancy derived from T lymphoc...

Impact of pre-transplant anxiety and depression on outcomes of AML patients after allogeneic transplantation

Neda Amirmokhtari, Hannah Katz, Elizabeth Muenks et al. Nov 03, 2025 pp. 2851-2851 10.1182/blood-2025-2851

Abstract Introduction: Allogeneic stem cell transplantation (Allo-SCT) in Acute Myeloid Leukemia (AML) is an important part of the treatment...

Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial

Nadja Jaekel, Susann Schulze, Christina Zahn et al. Nov 03, 2025 pp. 3804-3804 10.1182/blood-2025-3804

Abstract About 20% of myelofibrosis (MF) patients (pts) progress to MPN-blast phase (MPN-BP) which is preceded by an accelerated phase (MPN-...

Novel use of low-dose cidofovir (2.5 mg/kg Weekly) as CMV prophylaxis in the pre-engraftment Phase of stem cell transplantation: A viable alternative when ganciclovir is contraindicated and letermovir is not available

Santanu Sen, Nirali Sanghvi, Manam Mehra et al. Nov 03, 2025 pp. 7719-7719 10.1182/blood-2025-7719

Abstract Background: Cytomegalovirus (CMV) infection in the pre-engraftment phase of hematopoietic stem cell transplantation (HSCT) poses a...

Mosunetuzumab and lenalidomide combination therapy augments CD8+ T cells with enhanced T cell-dependent cytotoxicity against follicular lymphoma cells

Hayato Mizuta, Koh Furugaki, Sei Shu et al. Nov 03, 2025 pp. 1806-1806 10.1182/blood-2025-1806

Abstract Introduction Follicular lymphoma (FL) represents most common form of indolent non-Hodgkin lymphoma. Despite sig...

Real-world outcomes in relapsed/refractory multiple myeloma: Retreatment versus no retreatment with an anti-CD38 monoclonal antibody in the 2L and 3L in patients from the Flatiron Health database

María Nieto, Katie Gravagna, Jiaqi Fang et al. Nov 03, 2025 pp. 4562-4562 10.1182/blood-2025-4562

Abstract Introduction: A growing number of patients (pts) with multiple myeloma (MM) receive anti-CD38 monoclonal antibodies (mAbs) in early...

Mechanistic study of the Cullin3-CRL3^KEAP1-NRF2 neddylation axis in chemotherapy resistance of Acute Myeloid Leukemia stem cells

Li Wang, AoShuang Huang, JiShi Wang Nov 03, 2025 pp. 5065-5065 10.1182/blood-2025-5065

Abstract Cullin3-CRL3^KEAP1-NRF2 neddylation axis is a core mechanism of chemotherapy resistance in leukemia stem cells (LSCs), and targetin...

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

Divaya Bhutani, Samuel Rubinstein, Rajshekhar Chakraborty et al. Nov 03, 2025 pp. 2194-2194 10.1182/blood-2025-2194

Abstract Background: Monoclonal Immunoglobulin deposition disease (MIDD) is characterized by non-amyloidogenic linear amorphous deposition o...

PARP inhibitors and the rising incidence of secondary myelodysplastic syndrome and acute myeloid leukemia: A comprehensive meta-analysis

Shehab Mohamed, Abdulrahman Al-Mashdali, Anas Babiker et al. Nov 03, 2025 pp. 7390-7390 10.1182/blood-2025-7390

Abstract Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the management of BRCA-mutated ovarian and breast canc...

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Umberto Vitolo, Johannes Duell, Juan Miguel Bergua Burgues et al. Nov 03, 2025 pp. 63-63 10.1182/blood-2025-63

Abstract Introduction: A proportion of newly diagnosed (1L) patients (pts) with LBCL are ineligible for standard curative chemotherapy with...

Survival determinants of hepatosplenic t-cell lymphoma (HSTCL): Analysis of an updated real-world pooled database

Philip Haddad, Sireesha Vutukuri, Ankita Gupta Nov 03, 2025 pp. 892-892 10.1182/blood-2025-892

Abstract Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare and highly aggressive peripheral T-cell lymphoma ch...

Bone mineral density findings in patients with sickle cell disease

Madeline Evans, Asif Alavi, Dhanwada Rao Nov 03, 2025 pp. 4725-4725 10.1182/blood-2025-4725

Abstract Background: Individuals with sickle cell disease (SCD) are at an increased risk of low bone mineral density (BM...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page